Hyderabad-based Dr. Reddy’s Laboratories Ltd on Thursday announced the launch of its anti-cancer drug Toripalimab in the Country.
The drug is the only immuno-oncology drug approved by various regulatory authorities around the world for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), an aggressive form of head and neck cancer that originates in the upper part of the throat.
Dr. Reddy’s will market it under the brand name Zytorvi in India.
At present, the standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin.